Your browser doesn't support javascript.
loading
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Murai, Junko; Zhang, Yiping; Morris, Joel; Ji, Jiuping; Takeda, Shunichi; Doroshow, James H; Pommier, Yves.
Afiliação
  • Murai J; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research (Ju.M., J.H.D., Y.P.), National Clinical Target Validation Laboratory (Y.Z., J.J.), and Division of Cancer Treatment and Diagnosis (Jo.M., J.H.D.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan (Ju.M., S.T.).
J Pharmacol Exp Ther ; 349(3): 408-16, 2014 Jun.
Article em En | MEDLINE | ID: mdl-24650937

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Camptotecina / Dacarbazina / Inibidores Enzimáticos / Inibidores de Poli(ADP-Ribose) Polimerases / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: J Pharmacol Exp Ther Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Camptotecina / Dacarbazina / Inibidores Enzimáticos / Inibidores de Poli(ADP-Ribose) Polimerases / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: J Pharmacol Exp Ther Ano de publicação: 2014 Tipo de documento: Article